New data confirm superior blood pressure reductions in diabetic patients treated with TWYNSTA®
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
List view / Grid view
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
16 June 2011 | By Novartis
Construction of this facility represents the most significant Novartis investment in Russia...
16 June 2011 | By Sanofi
Sanofi has entered into a research collaboration with Audion Therapeutics to develop potential treatments for hearing loss...
16 June 2011 | By The Scott Partnership
Greenphire, partners with Mytrus to deliver novel and efficient web-based solutions for clinical trial patients...
16 June 2011 | By Novartis
The US FDA has accepted for review its supplemental Biologics License Application...
16 June 2011 | By Abbott
Reata and Abbott announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes...
16 June 2011 | By AstraZeneca
AstraZeneca plans to establish a Predictive Science Centre in St. Petersburg...
16 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
15 June 2011 | By Pfizer
Pfizer Injectables, announced the addition of doxorubicin hydrochloride injection, USP...
14 June 2011 | By kdm communications limited
Technical Communities to distribute Tecan’s liquid handling platforms...
14 June 2011 | By Zyme Communications Ltd
Horizon Discovery has announced that it has successfully completed an eighteen month pilot program with Novartis...
14 June 2011 | By Abbott
The U.S. FDA approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat EPI due to cystic fibrosis...
14 June 2011 | By GlaxoSmithKline
GSK to acquire the remaining 51% equity interest of Shenzhen Neptunus...
13 June 2011 | By Corning Incorporated
Corning Inc., has hired Dr. Richard Eglen, as vice president and general manager of the Corning Life Sciences business segment...